Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression
Yi Shi, Fangfang Chen, Yuanyuan Weng, Hang Zeng, Gang Chen
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHepatocellular Carcinoma Treatment and Prognosis · Protein Tyrosine Phosphatases · Mechanisms of cancer metastasis
An incorrect Funding statement was provided “The author(s) declared that financial support was not received for this work and/or its publication.”. The correct Funding statement reads: “This study was supported by Joint Funds for the innovation of science and technology, Fujian province (No. 2021Y9214) and Natural Science Foundation of Fujian province (No. 2023J011259).”
In the abstract, “RPL28 was silenced by siRNA, and effects on cell proliferation, migration, and sorafenib sensitivity were assessed by CCK-8, migration assays, and IC50 determination.” is incorrect. This has been corrected to read: “RPL28 was silenced by siRNA, and effects on cell proliferation, and migration were assessed by CCK-8 and migration assays.”
The original version of this article has been updated.